Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions

Cancer Immunology, Immunotherapy

Volumn 64, Issue 7, 2015, Pages 831-842

  Willemen, Yannick ^a   Van den Bergh, Johan M J ^a   Lion, Eva ^a,b   Anguille, Sébastien ^a   Roelandts, Vicky A E ^a   Van Acker, Heleen H ^a   Heynderickx, Steven D I ^a,b   Stein, Barbara M H ^b   Peeters, Marc ^a   Figdor, Carl G ^c   Van Tendeloo, Viggo F I ^a   de Vries, I Jolanda ^c,d   Adema, Gosse J ^c   Berneman, Zwi N ^a,b   Smits, Evelien L J ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer immunotherapy; Cytotoxic T cells; Dendritic cells; Interferon alpha; mRNA electroporation; Natural killer cells

Indexed keywords

ALPHA INTERFERON; MESSENGER RNA; TUMOR ANTIGEN; WT1 PROTEIN; WT1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADAPTIVE IMMUNITY; ARTICLE; CELL ENGINEERING; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; ELECTROPORATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MONOCYTE; MONOCYTE DERIVED DENDRITIC CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ADOPTIVE IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASM; SECRETION (PROCESS); TRANSPLANTATION;

ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; ELECTROPORATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NEOPLASMS; RNA, MESSENGER; WT1 PROTEINS;

EID: 84933181770     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1688-2     Document Type: Article

References (47)

1. Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265–277. doi:10.1038/nrc3258
2. Van Tendeloo VF, Van de Velde A, Van Driessche A et al (2010) Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 107:13824–13829. doi:10.1073/pnas.1008051107
3. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915. doi:10.1038/nm1100
4. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN (2014) Clinical use of dendritic cells for cancer therapy. Lancet Oncol 15:e257–e267. doi:10.1016/s1470-2045(13)70585-0
5. Anguille S, Willemen Y, Lion E, Smits EL, Berneman ZN (2012) Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy 14:647–656. doi:10.3109/14653249.2012.693744
6. Anguille S, Lion E, Willemen Y, Van Tendeloo VF, Berneman ZN, Smits EL (2011) Interferon-alpha in acute myeloid leukemia: an old drug revisited. Leukemia 25:739–748. doi:10.1038/leu.2010.324
7. Kirkwood J (2002) Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 29:18–26
8. Atzpodien J, Kirchner H, Rebmann U et al (2006) Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 95:463–469. doi:10.1038/sj.bjc.6603271
9. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281. doi:10.1056/NEJMoa066838
10. Diamond MS, Kinder M, Matsushita H et al (2011) Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208:1989–2003. doi:10.1084/jem.20101158
11. + dendritic cells. J Exp Med 208:2005–2016. doi:10.1084/jem.20101159
12. Arico E, Belardelli F (2012) Interferon-alpha as antiviral and antitumor vaccine adjuvants: mechanisms of action and response signature. J Interferon Cytokine Res 32:235–247. doi:10.1089/jir.2011.0077
13. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S (2012) Immunotherapy of cancer in 2012. CA Cancer J Clin 62:309–335. doi:10.3322/caac.20132
14. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I (2011) Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 17:2619–2627. doi:10.1158/1078-0432.ccr-10-1114
15. Smits EL, Lee C, Hardwick N, Brooks S, Van Tendeloo VF, Orchard K, Guinn BA (2011) Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunol Immunother 60:757–769. doi:10.1007/s00262-011-1022-6
16. Lion E, Smits EL, Berneman ZN, Van Tendeloo VF (2012) NK cells: key to success of DC-based cancer vaccines? Oncologist 17:1256–1270. doi:10.1634/theoncologist.2011-0122
17. Tel J, Aarntzen EH, Baba T et al (2013) Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 73:1063–1075. doi:10.1158/0008-5472.can-12-2583
18. Okada H, Tsugawa T, Sato H et al (2004) Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res 64:5830–5838. doi:10.1158/0008-5472.can-04-0130
19. Kuwashima N, Nishimura F, Eguchi J et al (2005) Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol 175:2730–2740
20. Huang C, Ramakrishnan R, Trkulja M, Ren X, Gabrilovich DI (2012) Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines. Cancer Immunol Immunother 61:573–579. doi:10.1007/s00262-011-1198-9
21. Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN (2001) Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98:49–56
22. Van Tendeloo VF, Ponsaerts P, Berneman ZN (2007) mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther 9:423–431
23. Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF (2009) Dendritic cell-based cancer gene therapy. Hum Gene Ther 20:1106–1118. doi:10.1089/hum.2009.145
24. Britten CM, Janetzki S, Butterfield LH et al (2012) T cell assays and MIATA: the essential minimum for maximum impact. Immunity 37:1–2. doi:10.1016/j.immuni.2012.07.010
25. Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Tureci O, Sahin U (2006) Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108:4009–4017. doi:10.1182/blood-2006-04-015024
26. Benteyn D, Anguille S, Van Lint S et al (2013) Design of an optimized Wilms’ Tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity in vitro and in vivo. Mol Ther Nucleic Acids 2:e134. doi:10.1038/mtna.2013.54
27. Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM, Berneman ZN, Van Tendeloo VF (2009) Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 11:653–668. doi:10.1080/14653240902960411
28. Lion E, Anguille S, Berneman ZN, Smits EL, Van Tendeloo VF (2011) Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS ONE 6:e20952. doi:10.1371/journal.pone.0020952
29. Rubinstein M, Levy WP, Moschera JA, Lai CY, Hershberg RD, Bartlett RT, Pestka S (1981) Human leukocyte interferon: isolation and characterization of several molecular forms. Arch Biochem Biophys 210:307–318
30. Hobbs DS, Pestka S (1982) Purification and characterization of interferons from a continuous myeloblastic cell line. J Biol Chem 257:4071–4076
31. Anguille S, Lion E, Tel J, de Vries IJ, Coudere K, Fromm PD, Van Tendeloo VF, Smits EL, Berneman ZN (2012) Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS ONE 7:e51851. doi:10.1371/journal.pone.0051851
32. Bonehill A, Tuyaerts S, Van Nuffel AM, Heirman C, Bos TJ, Fostier K, Neyns B, Thielemans K (2008) Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 16:1170–1180. doi:10.1038/mt.2008.77
33. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J (1998) Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161:1947–1953
34. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F (2000) Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191:1777–1788
35. Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, Tough DF (2002) Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99:3263–3271
36. Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, Morinobu A, Gadina M, O’Shea JJ, Biron CA (2002) Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297:2063–2066. doi:10.1126/science.1074900
37. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 174:4465–4469
38. Spadaro F, Lapenta C, Donati S, Abalsamo L, Barnaba V, Belardelli F, Santini SM, Ferrantini M (2012) IFN-alpha enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 119:1407–1417. doi:10.1182/blood-2011-06-363564
39. Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew FY, Caligiuri MA, Durbin JE, Biron CA (2002) Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 169:4279–4287
40. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P (2003) Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol 171:2366–2373
41. Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, Hertzog P, Smyth MJ (2007) Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 178:7540–7549
42. Lion E, Smits EL, Berneman ZN, Van Tendeloo VF (2009) Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells. Leuk Res 33:539–546. doi:10.1016/j.leukres.2008.08.020
43. Boudreau JE, Stephenson KB, Wang F et al (2011) IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res 71:2497–2506. doi:10.1158/0008-5472.can-10-3025
44. Jinushi M, Takehara T, Kanto T et al (2003) Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J Immunol 170:1249–1256
45. Elpek KG, Rubinstein MP, Bellemare-Pelletier A, Goldrath AW, Turley SJ (2010) Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proc Natl Acad Sci U S A 107:21647–21652. doi:10.1073/pnas.1012128107
46. Salguero G, Daenthanasanmak A, Munz C et al (2014) Dendritic cell-mediated immune humanization of mice: implications for allogeneic and xenogeneic stem cell transplantation. J Immunol 192:4636–4647. doi:10.4049/jimmunol.1302887
47. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E (2005) Natural-killer cells and dendritic cells: “l’union fait la force”. Blood 106:2252–2258. doi:10.1182/blood-2005-03-1154